Walvax Biotechnology Co. Ltd Financials

Market Capitalization CN¥18.12 Billion as of Jan. 1, 2026

Valuations Metrics as of Jan. 3, 2026

Trailing PE	363.67
Forward PE	24.24
Price to Sales TTM	CN¥7.27
Price to Book MRQ	CN¥1.80
Enterprise to Revenue	7.21
Enterprise to EBITDA	171.59

Financial Reports as of Jun. 30, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-06-30
Profit Margin	2.05%
Operating Margin	12.00%
Return on Assets TTM	-1.41%
Return on Equity TTM	-0.64%

Income Statement

Revenue TTM	CN¥2,398,903,040
Revenue per Share TTM	CN¥1.50
Quarterly Revenue Growth	-20.30%
Gross Profit TTM	CN¥1,612,515,840
EBITDA	CN¥837,073,834
Net Income to Common TTM	CN¥49,244,692
Diluted EPS TTM	CN¥0.03
Quarterly Earnings Growth YoY	40.20%

Balance Sheet

Total Cash MRQ	CN¥1,681,419,392
Total Cash per Share MRQ	CN¥1.05
Total Debt MRQ	CN¥
Total Debt to Equity MRQ	2.49
Current Ratio MRQ	3.52
Book Value per Share MRQ	CN¥6.05

Cash Flow

Operating Cash Flow TTM	CN¥556,811,968
Levered Free Cash Flow TTM	CN¥-1,173,012,096

300142 Stock Info as of Jan. 3, 2026

Stock Statistics

Shares Outstanding	1,599,348,541
Float Shares	1,430,185,446
Avg 10 Volume	18,945,269
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	12.19%
% Held by Institutions	10.39%

Stock Price Summary

Beta	0.44
Fifty Two Week Low	CN¥9.70
Fifty Two Week High	CN¥14.25
Fifty Two Week Change	-7.24%
Day 50 MA	CN¥11.81
Day 200 MA	CN¥11.52

Dividends and Splits

Forward Annual Dividend Rate	CN¥0.01
Forward Annual Dividend Yield	0.09%
Trailing Annual Dividend Rate	CN¥0.04
Trailing Annual Dividend Yield	0.36%
Payout Ratio	32.47%
Dividend Date
Ex Dividend Date	2025-05-28
Last Split Factor
Last Split Date	2015-10-14